Distinct angiogenic patterns are associated with high-grade in situ ductal carcinomas of the breast

Journal of Pathology

Volumn 181, Issue 2, 1997, Pages 207-212

  Engels, K ^a   Fox, S B ^a,b   Whitehouse, R M ^a   Gatter, K C ^a   Harris, A L ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Angiogenesis; DCIS; Immunohistochemistry

Indexed keywords

BLOOD CLOTTING FACTOR 7;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BREAST CARCINOMA; BREAST CARCINOMA IN SITU; CARCINOMA IN SITU; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS;

EID: 0031029433     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199702)181:2<207::AID-PATH758>3.0.CO;2-4     Document Type: Article

References (51)

1. Lagios MD. Duct carcinoma in situ. Pathology and treatment. Surg Clin North Am 1990; 70: 853-871.
2. van Dongen JA, Bartelink H, Fentiman IS, Peterse JL. Ductal carcinoma in situ (DCIS) of the breast - a therapeutic dilemma. Eur J Surg Oncol 1987; 13: 123-125.
3. van Dongen JA, Holland R, Peterse JL, et al. Ductal carcinoma in-situ of the breast; second EORTC consensus meeting [see comments]. Eur J Cancer 1992; 28: 626-629.
4. Bellamy CO, McDonald C, Salter DM, Chetty U, Anderson TJ. Noninvasive ductal carcinoma of the breast: the relevance of histologic categorization. Hum Pathol 1993; 24: 16-23.
5. Page DL, Anderson TJ, Rogers LW. Carcinoma in situ (CIS). In: Page DL ed. Diagnostic Histopathology of the Breast., Edinburgh: Churchill Livingstone, 1987; 157-192.
6. Poller DN, Silverstein MJ, Galea M, et al. Ideas in pathology. Ductal carcinoma in situ of the breast: a proposal for a new simplified histological classification association between cellular proliferation and c-crbB-2 protein expression. Mod Pathol 1994; 7: 257-262.
7. Silverstein MJ, Poller DN, Waisman JR, et al. Prognostic classification of breast ductal carcinoma-in-situ. Lancet 1995; 345: 1154-1157.
8. Holland R, Peterse JL, Millis RR, et al. Ductal carcinoma in situ: a proposal for a new classification. Semin Diagn Pathol 1994; 11: 167-180.
9. Leal CB, Schmitt FC, Bento MJ, Maia NC, Lopes CS. Ductal carcinoma in situ of the breast. Histologicl categorization and its relationship to ploidy and immunohistochemical expression of hormone receptors, p53, and c-erbB-2 protein. Cancer 1995; 75: 2123-2131.
10. Ramachandra S, Machin L, Ashley S, Monaghan P, Gusterson BA. Immunohistochemical distribution of c-erbB-2 in situ breast carcinoma - a detailed morphological analysis. J Pathol 1990; 161: 7-14.
11. Liu E, Thor A, He M, Barcos M, Ljung BM, Benz C. The HER2 (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast. Oncogene 1992; 7: 1027-1032.
12. Zafrani B, Leroyer A, Fourquet A, et al. Mammographically-detected ductal in situ carcinoma of the breast analyzed with a new classification. A study of 127 cases: correlation with estrogen and progesterone receptors, p53 and c-erbB-2 proteins, and proliferative activity. Semin Diagn Pathol 1994; 11: 208-214.
13. Bobrow LG, Happerfield LC, Gregory WM, Millis RR. Ductal carcinoma in situ: assessment of necrosis and nuclear morphology and their association with biological markers. J Pathol 1995; 176: 333-341.
14. Poller DN, Roberts EC, Bell JA, Elston CW, Blamey RW, Ellis IO. p53 protein expression in mammary ductal carcinoma in situ: relationship to immunohistochemical expression of estrogen receptor and c-erbB-2 protein. Hum Pathol 1993; 24: 463-468.
15. Pallis L, Skoog L, Falkmer U, et al. The DNA profile of breast cancer in situ. Eur J Surg Oncol 1992; 18: 108-111.
16. Cowan WK, Angus B, Henry J, Corbett IP, Reid WA, Horne CH. Immunohistochemical and other features of breast carcinomas presenting clinically compared with those detected by cancer screening. Br J Cancer 1991; 64: 780-784.
17. Stratton MR, Collins N, Lakhani SR, Sloane JP. Loss of heterozygosity in ductal carcinoma in situ of the breast. J Pathol 1995; 175: 195-201.
18. Radford DM, Fair K, Thompson AM, et al. Allelic loss of a chromosome 17 in ductal carcinoma in situ of the breast. Cancer Res 1993; 53: 2947-2949.
19. Radford DM, Fair KL, Phillips NJ, et al. Allelotyping of ductal carcinoma in situ of the breast: deletion of loci on 8p, 13q, 16q, 17p and 17q. Cancer Rex 1995; 55: 3399-3405.
20. Blood CH, Zetter BR. Tumor interactions with the vasculature: angiogenesis and tumor metastasis. Biochim Biophys Acta 1990; 1032: 89-118.
21. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989; 339: 58-61.
22. Smith MK, Weidner N. Demonstration and characterization of the angiogenic properties of cervical dysplasia. Cancer Res 1994; 54: 800-804.
23. Guidi AJ, Ahu-Jawdeh G, Berse B, et al. Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia. J Natl Cancer Inst 1995; 87: 1237-1245.
24. Chodak GW, Hospelhorn V, Gittes R, Folkman J. Angiogenic activity as a marker of neoplastic and pre-neoplastic lesions of the human bladder. Ann Surg 1981; 192: 762-771.
25. Guidi AJ, Fischer L, Harris JR, Schnitt SJ. Microvessel density and distribution in ductal carcinoma in situ of the breast. J Natl Cancer Inst 1994; 86: 614-619.
26. Brem SS, Gullino PM, Medina D. Angiogenesis: a marker for neoplastic transformation of mammary papillary hyperplasia. Science 1977; 195: 880-882.
27. Brem SS, M.JH, Gullino PM. Angiogenesis as a marker of pre-neoplastic lesions of the human breast. Cancer 1978; 41: 239-248.
28. Gimbrone MJ, Gullino PM. Angiogenic capacity of preneoplastic lesions of the murine mammary gland as a marker of neoplastic transformation. Cancer Res 1976;
29. Gimbrone MJ, Gullino PM. Neovascularization induced by intraocular xenografts of normal, preneoplastic, and neoplastic mouse mammary tissues. J Natl Cancer Inst 1976; 56: 305-318.
30. Ottinetti A, Sapino A. Morphometric evaluation of microvessels surrounding hyperplastic and neoplastic mammary lesions. Breast Cancer Res Treat 1988; 11: 241-248.
31. Knighton D, Ausprunk D, Tapper D, Folkman J. Avascular and vascular phases of tumour growth in the chick embryo. Br J Cancer 1977; 35: 347-356.
32. Sutherland RM, McCredie JA, Inch WR. Growth of multicell spheroids in tissue culture as a model of nodular carcinomas. J Natl Cancer Inst 1971; 46: 113-120.
33. Sutherland RM. Cell and environment interactions in tumor microregions: the multicell spheroid model. Science 1988; 240: 177-184.
34. Folkman J, Hochberg M. Self-regulation of growth in three dimensions. J Exp Med 1973; 138: 745-753.
35. Guinebretiere JM, Le MG, Gavoille A, Bahi J, Contesso G. Angiogenesis and risk of breast cancer in women with fibrocystic disease [letter; comment]. J Natl Cancer Inst 1994; 86: 635-636.
36. Bosari S, Lee AK, DeLellis RA, Wiley BD, Heatley GJ, Silverman ML. Microvessel quantitation and prognosis in invasive breast carcinoma. Hum Pathol 1992; 23: 755-761.
37. Horak ER, Leek R, Klenk N, et al. Angiogenesis, assessed by platelet/ endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 1992; 340: 1120-1124.
38. Bundred N, Bowcott M, Walls J, Faragher E, Knox F. Angiogenesis in breast cancer predicts node metastasis and survival. Br J Surg 1994; 81: 768 (Abstract).
39. Jaeger T, Weidner N, Chew K, et al. Tumor angiogenesis predicts lymph node metastasis in invasive bladder cancer. Proc Am Assoc Cancer Res 1994; 35: 66 (Abstract 394).
40. Ogawa Y, Chung Y, Nakata B, et al. An evaluation of angiogenesis in breast cancer with Factor VIII related antigen staining. Proc Am Assoc Cancer Res 1994; 35: 186 (Abstract 1113).
41. Ogawa Y, Chung YS, Nakata B, et al. Microvessel quantitation in invasive breast cancer by staining for Factor VIII-related antigen. Br J Cancer 1995; 71: 1297-1301.
42. Toi M, Kashitani J, Tominaga T. Tumor angiogenesis is an independent prognostic indicator in primary breast carcinoma. Int J Cancer 1993; 55: 371-374.
43. Weidner N, Semple JP, Welch WR, Foldman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991; 324: 1-8.
44. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993; 143: 401-409.
45. Porter PI., Patton KF, Self SA, Gown AM, Schmidt RA. A quantitative study of blood vessel size and density in normal and neoplastic breast tissue. Mod Pathol 1993; 6: 18; USCAP Abstract 87.
46. Schwartz GF, Finkel GC, Garcia JC, Patchefsky AS. Subclinical ductal carcinoma in situ of the breast. Treatment by local excision and surveillance alone [see comments]. Cancer 1992; 70: 2468-2474.
47. Solin LJ, Yeh IT, Kurtz J, et al. Ductal carcinoma in situ (intraductal carcinoma) of the breast treated with breast-conserving surgery and definitive irradiation. Correlation of pathologic parameters with outcome of treatment. Cancer 1993; 71: 2532-2542.
48. Fox S, Turner G, Gatter K, Harris A. The increased expression of adhesion molecules ICAM-3, E and P select in on breast cancer endothelium. J Pathol 1995; 177: 369-376.
49. Chaplain MA, Stuart AM. A model mechanism for the chemotactic response of endothelial cells to tumour angiogenesis factor. J Math Appl Med Biol 1993; 10: 149-168.
50. Chaplain MAJ, Giles SM, Sleeman BD, Jarvis RJ. A mathematical analysis of a model for tumour angiogenesis. J Math Biol 1995; 33: 744-770.
51. Mukhopadhyay D, Tsiokas L, Zhou XM, Foster D, Brugge JS, Sukhatme VP. Hypoxic induction of human vascular endothelial growth factor expression through c-Src activtion. Nature 1995; 375: 577-581.